What is the recommended treatment approach for gestational diabetes?

Treatment of Gestational Diabetes

Lifestyle modification with medical nutrition therapy and exercise should be the first-line treatment for gestational diabetes, with insulin as the preferred pharmacologic agent when lifestyle measures fail to achieve glycemic targets. 1

Initial Management: Lifestyle Modifications

Medical Nutrition Therapy

• An individualized nutrition plan developed with a registered dietitian is essential, providing minimum 175g carbohydrate daily (35% of 2,000-calorie diet), 71g protein, and 28g fiber 1
• The plan should emphasize monounsaturated and polyunsaturated fats while limiting saturated fats and avoiding trans fats 1
• Approximately 70-85% of women diagnosed with GDM under Carpenter-Coustan criteria can achieve glycemic control with lifestyle modification alone 1

Physical Activity

• Exercise interventions improve glucose outcomes and reduce insulin requirements 1
• Effective regimens include aerobic, resistance, or combined exercise for 20-50 minutes per day, 2-7 days per week at moderate intensity 1

Glycemic Targets During Treatment

• Fasting glucose <95 mg/dL (<5.3 mmol/L) 1
• One-hour postprandial glucose <140 mg/dL (<7.8 mmol/L) OR two-hour postprandial glucose <120 mg/dL (<6.7 mmol/L) 1

Pharmacologic Therapy When Lifestyle Fails

Insulin: First-Line Pharmacologic Agent

Insulin is the recommended first-line pharmacologic treatment for GDM in the United States because it does not cross the placenta and has well-established safety data 1, 2. Treatment with lifestyle modifications plus insulin has been demonstrated to improve perinatal outcomes in large randomized studies 1.

Oral Agents: Alternative Options with Important Caveats

Metformin

While metformin shows some efficacy in reducing glucose levels 1, it is not recommended as first-line treatment because it crosses the placenta and raises concerns about long-term offspring safety 1:

• Metformin results in umbilical cord blood levels as high or higher than maternal levels 1
• The 9-year follow-up data from the MiG TOFU study showed offspring exposed to metformin were heavier with higher waist-to-height ratios and waist circumferences compared to insulin-exposed offspring (Auckland cohort) 1
• Meta-analyses demonstrate metformin exposure results in smaller neonates with accelerated postnatal growth, leading to higher childhood BMI 1
• A 2015 meta-analysis concluded that metformin (plus insulin when required) performs slightly better than insulin for some outcomes, with less maternal weight gain and fewer large-for-gestational-age infants but higher preterm birth rates 1

Clinical consideration: Despite not being first-line, metformin may be considered when insulin cannot be prescribed, though up to 46% of women may require additional insulin for adequate glycemic control 3. Some countries consider it first-line treatment based on reassuring short-term safety data 4.

Glyburide (Sulfonylureas)

Glyburide is inferior to both insulin and metformin and should be avoided 1:

• Glyburide crosses the placenta with cord plasma concentrations approximately 50-70% of maternal levels 1
• Meta-analyses show glyburide is associated with higher birth weight, more frequent macrosomia, and increased neonatal hypoglycemia compared to both insulin and metformin 1
• There are no long-term safety studies evaluating offspring outcomes after glyburide exposure 1
• It should only be used when benefits clearly surpass possible risks 4

Monitoring and Follow-up

• Self-monitoring of capillary glucose is recommended to assess glycemic control 5
• Recent evidence suggests continuous glucose monitoring (CGM) in early GDM (diagnosed at 8-26 weeks) significantly reduces unscheduled cesarean sections (20.0% vs 44.4%), preterm deliveries (6.8% vs 18.4%), large-for-gestational-age rates (5.0% vs 18.4%), and NICU admissions (22.5% vs 44.7%) compared to standard self-monitoring 6

Common Pitfalls to Avoid

• Do not use glyburide as first-line therapy given its association with worse neonatal outcomes compared to insulin and metformin 1
• Do not assume metformin is equivalent to insulin - counsel patients about placental transfer and potential long-term offspring metabolic effects 1
• Do not delay insulin initiation when oral agents fail to achieve glycemic targets, as up to 46% of women on metformin require supplemental insulin 3
• Recognize that women with diet-controlled GDM can await spontaneous labor, but those requiring insulin therapy should have elective induction at term recommended 3